Population
Patients with hypertrophic cardiomyopathy (HCM)
Design
Review
Loading...
HCM's benign course with SCD risk in youth leaves open refined stratification; supports targeted prevention research.
This review highlights the molecular genetic basis of hypertrophic cardiomyopathy, emphasizing the role of sarcomere gene variants and their translation into targeted therapies such as mavacamten.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: